| 2023-03-02 15:32 | CC:AWKN | Awakn Life Sciences Corp | 0.39 | News Release200 | Pharmala Biotech to supply MDMA to Awakn |
| 2023-02-28 13:01 | CC:AWKN | Awakn Life Sciences Corp | 0.36 | News Release200 | Awakn Life Sciences signs 4th licensing deal in N.A. |
| 2023-02-21 10:42 | CC:AWKN | Awakn Life Sciences Corp | 0.46 | News Release200 | Awakn Life Sciences signs first European licensing deal |
| 2023-02-14 12:52 | CC:AWKN | Awakn Life Sciences Corp | 0.465 | News Release200 | Awakn Life opens second ketamine clinic in Norway |
| 2023-02-09 10:53 | CC:AWKN | Awakn Life Sciences Corp | 0.60 | News Release200 | Awakn begins MDMA FS with Catalent's Zydis ODT tech |
| 2023-02-08 18:37 | CC:AWKN | Awakn Life Sciences Corp | 0.60 | News Release200 | Awakn acknowledges recent promotional activity |
| 2023-02-07 10:19 | CC:AWKN | Awakn Life Sciences Corp | 0.53 | News Release200 | Awakn Life receives fast-track designation in U.K. |
| 2023-01-24 10:46 | CC:AWKN | Awakn Life Sciences Corp | 0.33 | News Release200 | Awakn starts (S)-ketamine investigative study |
| 2022-12-15 12:03 | CC:AWKN | Awakn Life Sciences Corp | 0.335 | News Release200 | Awakn talks revenue, omits Q3 2022 P&L in NR |
| 2022-12-15 07:39 | CC:AWKN | Awakn Life Sciences Corp | 0.355 | SEDAR Interim Financial Statements812 | SEDAR Interim Financial Statements |
| 2022-12-15 07:33 | CC:AWKN | Awakn Life Sciences Corp | 0.355 | SEDAR MD & A815 | SEDAR MD & A |
| 2022-12-13 11:45 | CC:AWKN | Awakn Life Sciences Corp | 0.35 | News Release200 | Awakn to conduct phase III trial at 7 NHS sites in U.K. |
| 2022-12-01 12:24 | CC:AWKN | Awakn Life Sciences Corp | 0.42 | News Release200 | Awakn signs five-year lease for 2nd clinic in Norway |
| 2022-11-23 10:53 | CC:AWKN | Awakn Life Sciences Corp | 0.34 | News Release200 | Awakn signs five-year lease for larger Oslo clinic |
| 2022-11-17 12:19 | CC:AWKN | Awakn Life Sciences Corp | 0.39 | News Release200 | Awakn closes $1.86M second tranche of financing |
| 2022-11-09 15:52 | CC:AWKN | Awakn Life Sciences Corp | | News Release200 | Awakn Life Sciences signs 3rd licensing deal in N.A. |
| 2022-10-25 12:45 | CC:AWKN | Awakn Life Sciences Corp | 0.33 | News Release200 | Awakn Life Sciences arranges $775,000 loan from TD Veen |
| 2022-09-15 12:51 | CC:AWKN | Awakn Life Sciences Corp | 0.56 | News Release200 | Awakn talks revenue, omits Q2 2022 P&L in NR |
| 2022-09-14 19:04 | CC:AWKN | Awakn Life Sciences Corp | 0.57 | SEDAR MD & A815 | SEDAR MD & A |
| 2022-09-14 18:56 | CC:AWKN | Awakn Life Sciences Corp | 0.57 | SEDAR Interim Financial Statements812 | SEDAR Interim Financial Statements |
| 2022-09-12 12:10 | CC:AWKN | Awakn Life Sciences Corp | 0.57 | News Release200 | Awakn signs deal to conduct FS with MDMA, Zydis |
| 2022-08-25 10:02 | CC:AWKN | Awakn Life Sciences Corp | 0.60 | News Release200 | Awakn signs 12-month option for Project Kestrel |
| 2022-08-18 09:47 | CC:AWKN | Awakn Life Sciences Corp | 0.65 | News Release200 | Awakn signs licensing partnership with Wellbeings |
| 2022-08-15 11:11 | CC:AWKN | Awakn Life Sciences Corp | 0.53 | News Release200 | Awakn licenses AUD therapy treatment to Revitalist |
| 2022-07-20 09:58 | CC:AWKN | Awakn Life Sciences Corp | 0.70 | News Release200 | Awakn receives $2.5M of funding for AUD therapy trial |
| 2022-07-15 10:25 | CC:AWKN | Awakn Life Sciences Corp | 0.78 | News Release200 | Awakn begins beta phase of licensing business |
| 2022-07-05 11:01 | CC:AWKN | Awakn Life Sciences Corp | 0.59 | News Release200 | Awakn Life receives U.K. funding for AUD therapy |
| 2022-06-14 17:50 | CC:AWKN | Awakn Life Sciences Corp | 0.70 | News Release200 | Awakn talks momentum, omits Q1 P&L from NR |
| 2022-06-14 17:11 | CC:AWKN | Awakn Life Sciences Corp | 0.70 | SEDAR Interim Financial Statements812 | SEDAR Interim Financial Statements |
| 2022-06-14 17:11 | CC:AWKN | Awakn Life Sciences Corp | 0.70 | SEDAR MD & A815 | SEDAR MD & A |
| 2022-06-07 13:31 | CC:AWKN | Awakn Life Sciences Corp | 1.05 | News Release200 | Awakn appoints Purcell as special adviser to CEO |
| 2022-06-02 10:17 | CC:AWKN | Awakn Life Sciences Corp | 1.23 | News Release200 | Awakn begins behavioural study on gambling disorder |
| 2022-05-26 17:14 | CC:AWKN | Awakn Life Sciences Corp | 1.21 | News Release200 | Awakn files patent application for ketamine treatment |
| 2022-05-19 10:41 | CC:AWKN | Awakn Life Sciences Corp | 1.35 | News Release200 | Awakn Life Sciences completes ketamine treatment study |
| 2022-05-17 13:18 | CC:AWKN | Awakn Life Sciences Corp | 1.26 | News Release200 | Awakn Life Sciences appoints Dhandayudham as CMO |
| 2022-04-28 17:56 | CC:AWKN | Awakn Life Sciences Corp | 1.30 | News Release200 | Awakn talks revenue, omits fiscal 2022 P&L in NR |
| 2022-04-28 16:54 | CC:AWKN | Awakn Life Sciences Corp | 1.30 | SEDAR Annual Information Form802 | SEDAR Annual Information Form |
| 2022-04-28 16:54 | CC:AWKN | Awakn Life Sciences Corp | 1.30 | SEDAR Audited Annual Financial Statements804 | SEDAR Audited Annual Financial Statements |
| 2022-04-28 16:54 | CC:AWKN | Awakn Life Sciences Corp | 1.30 | SEDAR MD & A815 | SEDAR MD & A |
| 2022-04-13 12:01 | CC:AWKN | Awakn Life Sciences Corp | 1.55 | News Release200 | Awakn Life Sciences talks U.K., Norway clinics |
| 2022-04-06 11:54 | CC:AWKN | Awakn Life Sciences Corp | 1.60 | News Release200 | Awakn Life completes phase 1 of drug discovery program |